One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [<sup>177</sup>Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting.
Sandip Basu(Bhabha Atomic Research Centre), Sharmila Banerjee(Bhabha Atomic Research Centre), Bhawna Sirohi(Royal Marsden Hospital), Geeta Sonawane(Homi Bhabha National Institute), Vikas Ostwal(Homi Bhabha National Institute), Rohit Ranade(Homi Bhabha National Institute), Swapna Nabar(Homi Bhabha National Institute), Sudipta Chakraborty, Shailesh V. Shrikhande(Homi Bhabha National Institute), Hemant Shimpi(Homi Bhabha National Institute), Pradeep Thapa(Homi Bhabha National Institute), Anant Ramaswamy(Homi Bhabha National Institute), Manish Bhandare(Homi Bhabha National Institute), Ashok Chandak(Homi Bhabha National Institute), Ashutosh Dash(Bhabha Atomic Research Centre), Kamaldeep(Bhabha Atomic Research Centre), Ramesh Asopa(Homi Bhabha National Institute), Vikram Chaudhari(Homi Bhabha National Institute), K.V. Vimalnath(Bhabha Atomic Research Centre), Rahul V. Parghane(Homi Bhabha National Institute)
PubMed
January 1, 2020
Cited by 7
Related Papers
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation
|The Hematology Journal|2003|425
Production of 177Lu for Targeted Radionuclide Therapy: Available Options
|Nuclear Medicine and Molecular Imaging|2015|375
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
|The Lancet. Gastroenterology & hepatology|2024|245
Environmental and occupational determinants of lung cancer
|Translational Lung Cancer Research|2019|171